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E-mail addresses: nokita7@rs.noda.tus.ac.jp, nmsokCHK1 regulates the DNA damage-induced checkpoint involving an ATR- or ATM- dependent path-
way. In this paper, we focused on the autophosphorylation of Ser296, one of the DNA damage-
induced phosphorylation sites. First, we demonstrated that the Ser296 autophosphorylation of
CHK1 is mainly regulated by an intramolecular mechanism in response to DNA damage. In examin-
ing the relationship between Ser296 and Ser317/Ser345, the other ATR dependent phosphorylation
sites, we found that the Ser296 cis-autophosphorylation was dependent on both Ser317 and Ser345
phosphorylation. Our ﬁndings suggest that CHK1 mediates cell cycle checkpoint signals by both cis-
autophosphorylation and trans-phosphorylation of downstream factors.
Structured summary of protein interactions:
CHK1 phosphorylates CHK1 by protein kinase assay (View Interaction: 1, 2, 3)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
CHK1 is an evolutionarily conserved serine/threonine protein
kinase that maintains genomic integrity through S and G2/M
checkpoint regulation [1]. Since CHK1 inhibition enhances cell
death induction by chemical DNA damage agents, ultraviolet, or
ionizing radiation, CHK1 is an attractive target for cancer therapy
[1]. In response to various initiators of DNA damage, CHK1 is
mainly phosphorylated by ATR or ATM, which are members of
the phosphatidylinositol 3-kinase-related protein kinases family
(PIKKs) and key molecules in the recognition of DNA damage [1].
CHK1 then phosphorylates various downstream effectors, such as
CDC25 phosphatases [2–5] and p53 [6] leading to cell cycle arrest.
Recently, it was reported that Histone H3 is a novel substrate of
CHK1, and that Histone H3 phosphorylation by CHK1 is involved
in DNA damage-induced transcriptional repression of cell cycle
factors such as Cyclin B1 [7,8]. Furthermore, CHK1 plays roles not
only in the DNA damage checkpoint but also in cell growth, cell
cycle progression and cell death [9–15].
It has been reported that CHK1 is phosphorylated at multiple
sites in response to DNA damage. ATR-mediated phosphorylation
at Ser317 and Ser345 is required for the release of CHK1 from
chromatin and its translocation to the cytoplasm, followed bychemical Societies. Published by E
ita@gmail.com (N. Okita).Fbx6-mediated ubiquitin-proteasomal degradation [16–18]. Muta-
tion of Ser317 or Ser345 causes DNA damage checkpoint defects
[17]. Furthermore, another DNA damage responsive phosphoryla-
tion site, Ser296, has been reported after UV, hydroxyurea, or res-
veratrol treatment [19–21]. Recently, it was reported that Ser296 is
an autophosphorylation site and is required in the G2/M check-
point via 14–3-3 c-mediated CDC25A proteolysis [22]. In this
study, to elucidate the mechanisms involved in the CHK1-mediated
DNA damage checkpoint pathway, we analyzed the mode of
autophosphorylation and the relationships between Ser296,
Ser317 and Ser345 phosphorylation.
2. Materials and methods
2.1. Cell culture
U2OS and HeLaS3 cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) low glucose supplemented with 10% fetal
calf serum (FCS) (Bovogen, Australia), 1% Penicillin–Streptomycin
solution (Sigma, USA). U2OS tet-on cells (Clontech, Japan) were
maintained in DMEM low glucose containing 10% FCS, 1% Penicil-
lin–Streptomycin solution, and 200 lg/mL G418 (Wako, Japan).
ATR mutated cells, ATR-seckel/hTert (Seckel), and ATR proﬁcient
cells, 1BR-3/hTert (1BR) were cultured in DMEM high glucose sup-
plemented with 10% FCS, 1% Penicillin–Streptomycin solution, and
0.4 l/mL puromycin (Wako, Japan) [23].lsevier B.V. All rights reserved.
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Hydroxyurea (Hu), thymidine (Thy), cisplatin (Cis), camptothe-
cin (Cpt), nocodazole (Noc), and tunicamycin (Tu) were purchased
from Wako (Japan). Etoposide (Etp) and zeocin (Zeo) were from
Enzo Life Sciences (USA) and Invitrogen (USA), respectively.
SB218078 was purchased from Tocris Bioscience (USA).
2.3. siRNA
StealthRNAi (Invitrogen, USA) for GFP (siScr), ATM (siATM), and
ATR (siATR) were prepared as follows: siScr, 50-CCAACUUGUCUGG
UGUCAAAAAUAA-30, 50- UUAUUUUUGACACCAGACAAGUUGG-30;
siATM, 50-UAAGCAGAUCAUUAAGUACUAGACU-30, 50-AGUCUAGUA
CUUAAUGAUCUGCUUA-30; siATR, 50-AAAUCAAGCAACAUCAC
GGAGGUUG-30, 50-CAACCUCCGUGAUGUUGCUUGAUUU-30. siRNA
transfection was performed using Lipofectamine RNAiMAX accord-
ing to the manufacturer’s protocol.
2.4. Site-directed mutagenesis and vector construction
Lys38 and Asp130 are essential for CHK1 kinase activity. Ala sub-
stitution mutants for these sites (K38A and D130A, respectively)
have been identiﬁed as kinase inactive mutations [3,24], and
characterized [25]. All CHK1 mutants were constructed using site-
directed mutagenesis using the following primers; K38A, forward
50-GTAACTGAAGAAGCAGTCGCAGTGGCGATTGTAGATATGAAGCGT
GCCG-30 and reverse 50-CGGCACGCTTCATATCTACAATCGCCACTGC
GACTGCTTCTTCAGTTAC-30; D130A, forward 50-GGAATAACTCAC
AGGGCTATTAAACCAGAAAATCTTC-30 and reverse 50-GAAGATTTTC
TGGTTTAATAGCCCTGTGAGTTATTCC-30; S296A, forward 50-GGATT
TTCTAAGCACATTCAAGCCAATTTGGACTTCTCTCCAG-30 and reverse
5’-CTGGAGAGAAGTCCAAATTGGCTTGAATGTGCTTAGAAAATCC-30;
S317A, forward 50-GAAAATGTGAAGTACTCCAGTGCTCAGCCAGAAC
CCCGCACAGG-30 and reverse 50-CCTGTGCGGGGTTCTGGCTGAGC
ACTGGAGTACTTCACATTTTC-30; S345A, forward 50-GGTACAAGGGA
TCAGCTTTGCCCAGCCCACATGTCCTG-30 and reverse 50-CAGGACAT
GTGGGCTGGGCAAAGCTGATCCCTTGTACC-30.
2.5. Stable transfection
U2OS cells were transfected with NruI-linearized pIRES-Neo3
vectors containing CHK1 WT (wild-type), CHK1 D130A, or CHK1
S296A cDNA using the Fugene HD transfection reagent according
to the manufacturer’s protocol. Each stable transfectant was se-
lected using 1 mg/mL G418. For clone isolations, individual
G418-resistant colonies were isolated with a cloning cylinder. For
each isolated clone we checked expression levels of exogenous
CHK1 protein expression by Western blotting. Established U2OS-Chk1
cells were maintained in DMEM containing 10% FCS, 1% Penicillin–
Streptomycin solution, and 200 lg/mL G418.
2.6. Antibodies and Western blotting
Antibodies were purchased as follows: Rabbit anti-CHK1
(pSer296) polyclonal antibody and rabbit anti-Chk1 (pSer345)
monoclonal antibody (clone 133D3) from Cell Signaling Technol-
ogy (USA); Rabbit anti-CHK1 (pSer296) (clone EPR915) monoclonal
antibody from Epitomics (USA); Rabbit anti-CHK1 (pS317) poly-
clonal antibody from R&D Systems (USA); Mouse anti-CHK1 (clone
DCS-310) from MBL (Japan); Mouse anti-b-actin monoclonal
antibody (clone AC-15) from Sigma (USA); Horseradish
peroxidase-conjugated goat anti-mouse antibody and horseradishperoxidase-conjugated goat anti-rabbit antibody from Jackson
Immunological Research (USA).
Cells were lyzed by the direct addition of Lysis buffer (50 mM
Tris–HCl pH6.8, 2% SDS, 5% glycerol) and boiled for 5 min. Protein
concentrations were determined using the BCA protein assay
(Pierce, USA) according to the manufacturer’s protocol, and stan-
dardized by the addition of lysis buffer. The protein solutions
were prepared for gel loading with 2-mercaptoethanol (5%) and
bromophenol blue (0.025%), and boiled for 5 min. Equal amounts
of proteins (5–20 lg) were subjected to Bis-tris SDS–PAGE and
transferred to nitrocellulose membranes. The membranes were
blocked with 2.5% skim milk and 0.25% BSA in Tris-buffered saline
(10 mM Tris–HCl pH 7.4, 150 mM NaCl) containing 0.1% Tween 20
(TTBS) for 1 h at room temperature, and then probed with appro-
priate primary antibodies overnight at 4 C or for 2 h at room tem-
perature. The membranes were subsequently washed with TTBS
and incubated with the appropriate secondary antibody for 1 h at
room temperature. After washing the membrane with TTBS, the
blotted proteins were visualized with a LAS3000 Luminescent Im-
age Analyzer (Fuji Film, Japan) using Supersignal West Femto Max-
imum Sensitivity Substrate (Pierce, USA) or ImmunoStar LD
reagent (Wako, Japan). Quantitative analysis of this data was per-
formed using Multigauge software (Fuji FILM).
2.7. Production of recombinant CHK1
For preparation of 3xFLAG-CHK1–3xMyc, U2OS tet-on cells
were transfected with NruI-linearized pTRE2-hyg vectors contain-
ing 3xFLAG-CHK1 WT-3xMyc or 3xFLAG-CHK1 D130A-3xMyc
cDNA using Fugene HD (Promega, USA) according to the manufac-
turer’s protocol. Each stable transfectant was selected using
600 lg/mL Hygromycin B. Established U2OS tet-on/CHK1 cells
were maintained in DMEM containing 10% FCS, 1% Penicillin–
Streptomycin solution, 120 lg/mL Hygromycin B, and 200 lg/mL
G418. For preparation of 3xFLAG-CHK1–3xMyc, U2OS tet-on/
CHK1 cells were grown in the presence of 5 lg/mL of doxycycline
for 2 days. The recombinant 3xFLAG-CHK1–3xMyc was puriﬁed
with anti-FLAG beads (Sigma) and anti-Myc beads (MBL).
For preparation of CHK1–6His, various CHK1 constructs includ-
ing a His-tag(6His) encoding sequence obtained by site-directed
mutagenesis were cloned into an EcoRI site of the pTnT vector
(Promega, USA). Recombinant CHK1s were produced by an
in vitro transcription/translation method with a TnT SP6-coupled
reticulocyte lysate system (Promega, USA). In brief, an in vitro
translation mixture containing the pTnT vector (40 ng/lL mixture)
was incubated at 30 C for 2 h. Recombinant CHK1–6His was puri-
ﬁed with immobilized metal afﬁnity chromatography using the
MagZ Protein Puriﬁcation System (Promega, USA).
2.8. CHK1 kinase assay
For autophosphorylation activity, recombinant CHK1s were
incubated in a kinase reaction buffer containing 20 mM HEPES-
NaOH (pH7.4), 1 mM ATP, 15 mM MgCl2, 0.5 mM DTT, 0.01%
NP-40, 5% glycerol, 1% protease inhibitor cocktails (Sigma, USA),
and 1% phosphatase inhibitor cocktails (Sigma, USA) at 37 C for
30 min. The reaction was then stopped by the addition of an equal
volume of 2x SDS sample buffer (100 mM Tris–HCl pH 6.8, 4% SDS,
10% 2-ME, 10% glycerol, 0.05% BPB). The autophosphorylation
activity was visualized using Western blotting and quantiﬁed by
chemiluminescence. For the detection of inter-phosphorylation, a
recombinant GST-CDC25C fragment was prepared as a substrate
[26], and subsequently CHK1 was incubated in CHK1 buffer with
the GST-CDC25C fragment.
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Fig. 1. CHK1 is phosphorylated at Ser296 in response to DNA damage. (A) HeLa S3
cells were treated with various stress-inducing agents for 12 h, and whole cell
lysates were subjected to Western blotting with the indicated antibodies. Hu,
2.5 mM Hydroxyurea. Thy, 3 mM Thymidine. Cis, 2 lM Cisplatin. Cpt, 2 lM
Camptothecin. 5 lM Etp, Etoposide. Zeo, 130 lM Zeocin. Noc, 300 nM Nocodazole.
Tun, 1 lM Tunicamycin. (B) U2OS or HeLa S3 cells were treated with Cis (U2OS:
5 lM, HeLaS3: 2 lM) or Etp (U2OS: 2 lM, HeLaS3: 5 lM) for 3 h. The cells were
harvested, and the cell lysates were analyzed by Western blotting with the
indicated antibodies. (C) HeLa S3 cells were transfected with 40 nM of a control
double-stranded RNA, an siRNA speciﬁc for ATM, or an siRNA speciﬁc for ATR, and
then treated with 2 lM Cis. After the indicated incubation times, the cells were
harvested and the lysates were analyzed by Western blotting with the indicated
antibodies. (D) ATR deﬁcient cells, ATR-seckel/hTert (Seckel), and ATR proﬁcient
cells, 1BR-3/hTert (1BR), were treated with 3 lM Cis or 500 lMHu for the indicated
times. The cells were harvested at the indicated times and the cell lysates were
analyzed by Western blotting with indicated antibodies. Asterisks indicate non-
speciﬁc bands.
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3.1. DNA-damaging agents induce autophosphorylation of CHK1 at
Ser296 in an ATR-dependent manner
To addresswhether only DNA damage induces Ser296 autophos-
phorylation, human osteosarcoma U2OS cells were treated with
various drugs; replication stress inducers (Hu and Thy), a DNA cross
linker (Cis), topoisomerase inhibitors (Cpt and Etp), a DNA strand
breaker (Zeo), a microtubule inhibitor (Noc) and a N-linked glyco-
sylation inhibitor (Tun) (Fig. 1A). The DNA damage-inducing agents,
including the replication stress inducers, the DNA cross linker, the
topoisomerase inhibitors, and the DNA strand breaker, induced
phosphorylation at Ser296 as well as Ser317, but the other stress
inducers did not. Furthermore, Ser296 phosphorylation induced
by DNA damagewas also detected in human cervical carcinoma He-
LaS3 cells (Fig. 1B). These results show that CHK1 is phosphorylated
at Ser296 in response to DNA damage in human cells. Considered
with the results of previous studies, we expected that PIKKs such
as ATM, ATR, or DNA-PK, which are important in the response to
DNA damage, could be involved in the phosphorylation of CHK1
at Ser296. Due to preliminary experiments using PIKKs inhibitors,
such as caffeine [27,28], wortmannin [29], and NU7026 [30,31]
which suggested the involvement of ATM and/or ATR in the phos-
phorylation of CHK1 at Ser296 (data not shown), a knockdown
study using siATM and siATR was performed (Fig. 1C). Treatment
by siATR but not siATM inhibited Cis-induced Ser296 and Ser317
phosphorylation. Furthermore, the experiments using Cis or HU-
treated ATR mutated ﬁbroblast cells, ATR seckel/hTERT, as well as
the control ﬁbroblast cells, 1BR/hTERT [23], provided similar results
(Fig. 1D). These results show that in Cis-induced DNA damage an
ATR-dependent pathway regulates phosphorylation of CHK1 at
Ser296 as well as those at Ser317 and Ser345.
3.2. Autophosphorylation of CHK1 at Ser296 is regulated by an
intramolecular mechanism
When analyzing the DNA damage response in cells expressing
WT (exoCHK1(WT)) or D130A kinase dead mutant (exoCHK1
(D130A)) fused FLAG- and Myc-tags, we obtained an interesting re-
sult (Fig. 2A). In cells expressing exoCHK1-WT, both endogenous
CHK1(endoCHK1) and exoCHK1(WT) were phosphorylated at
Ser296 (also Ser317 and Ser345) in response to Cis treatment.
On the other hand, surprisingly, in cells expressing exoCHK1
(D130A), only endoCHK1, but not exoCHK1(D130A), was phos-
phorylated at Ser296. This result suggests the possibility that
the Ser296 autophosphorylation is regulated by an intramolecu-
lar mechanism. We therefore sought to prove this hypothesis by
in vitro experiments using recombinant CHK1. For these experi-
ments we prepared wild-type (WT) or kinase-dead (KD) forms of
recombinant CHK1 fused tags with different molecular weights
(MW). Recombinant CHK1 constructs with higher MW (approxi-
mately 61.6 kDa) were tagged with both 3xFLAG (3F) and 3xMyc
(3M), and those with lower MW (approximately 55.5 kDa) were
tagged with 6xHis (6His). As shown in Fig. 2B, if Ser296 auto-
phosphorylation is by an intermolecular mechanism, Ser296 of
CHK1(KD) could be phosphorylated by CHK1(WT), and Ser296
of one CHK1(WT) molecule could be phosphorylated by the
other CHK1-WT molecules (upper panel). On the other hand, if
Ser296 autophosphorylation is by an intramolecular mechanism,
Ser296 of CHK1(KD) could neither be phosphorylated by itself nor
by CHK1(WT). As such, Ser296 of a CHK1(WT) molecule could be
phosphorylated by itself (lower panel). Since the MWs of CHK(WT)
and CHK1(KD) are different, they can be separated by SDS–PAGE. In
this strategy, it was important to minimize the side-effects ofmutations designed for the elimination of kinase activity on the
CHK1 structure. Therefore we prepared two KD mutants, K38A
and D130A. Lys38 and Asp130 are required to form an ATP-binding
pocket and a catalytic loop, respectively [25]. As shown in Fig. 2C,
only CHK1(WT)-6His was autophoshorylated during incubation
with ATP. After incubation without ATP, a basal level of Ser296
phosphorylation was only observed in CHK1(WT)-6His, and not in
the other mutants. This observation implies that the basal phos-
phorylation of recombinant CHK1 has already occurred in an
in vitro transcription/translation system. Next, to conﬁrm whether
Ser296 autophosphorylation is regulated by an intramolecular
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Fig. 2. CHK1 Ser296 is autophosphorylated by an intramolecular mechanism. (A)
U2OS cells stably expressing exoCHK1(WT) or (D130A)were treatedwith5 lMCis for
the indicated times. The cells were harvested, and the cell lysates were analyzed by
Western blotting with the indicated antibodies. (B) If Ser296 autophosphorylation is
regulated by an intermolecular mechanism, Ser296 of CHK1(KD) could be phosphor-
ylatedbyCHK1(WT). Ser296of oneCHK1(WT)molecule canbephosphorylatedby the
other CHK1-WTmolecules (upper panel). On the other hand, if Ser296 autophospho-
rylation is by an intra-molecular mechanism, Ser296 of CHK1(KD) cannot be
phosphorylated by itself, and Ser296 of one CHK1(WT) molecule could be phosphor-
ylated by the CHK1(WT) molecule (lower panel). (C and D) The indicated puriﬁed
recombinant CHK1–6His proteins (C) or the indicated sets of puriﬁed recombinant 3F-
CHK1–3 M or CHK1–6-His (D) were incubated in the presence or absence of ATP for
30 min at 30 C. The proteins were separated by SDS–PAGE and analyzed byWestern
blottingwith the indicated antibodies. After normalizationof Ser296phosphorylation
signal from a recombinant protein by its total CHK1 protein, we deﬁned the average
value of normalized Ser296 phosphorylation signals from wild-type forms of the
recombinant CHK1 proteins without ATP incubation as ‘‘1’’. Based on the deﬁnition,
relative levels of Ser296 phosphorylation (pSer296 levels) and levels of Ser296
phosphorylation increased by the addition of ATP (Increase) were shown.
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phosphorylation assay using the combinations shown in
(Fig. 2D). In the reaction combination of 3F-CHK1(WT)-3 M and
CHK1(WT)-6His, both Ser296 phosphorylation levels were increased
by the addition of ATP. However, in the reaction combinations of
3F-CHK1(WT)-3 M and CHK1(K38A)-6His or 3F-CHK1(WT)-3 M
and CHK1(D130A)-6His, only 3F-CHK1(WT)-3 M was efﬁciently
autophosphorylated at Ser296. To check for any unexpected
artifacts produced by recombinant preparation methods, we also
used a combination of 3F-CHK1(D130A)-3 M and CHK1(WT)-6His,
which gave a similar result. These results clearly show that
Ser296 autophosphorylation of CHK1 is mainly regulated by an
intramolecular mechanism.
3.3. The relationship between DNA damage-induced phosphorylation
at Ser296, Ser317, and Ser345
It has been reported that phosphorylations of Ser317 and
Ser345 are important for checkpoint regulation [17]. Considering
that Ser296 autophosphorylation by an intramolecular mechanism
(cis-autophosphorylation) is regulated in an ATR-dependent
manner as well as Ser317 and Ser345 phosphorylation (Fig. 1),
we addressed the relationships between the different DNA
damage-induced CHK1 phosphorylation sites. For this purpose
we established U2OS cell lines which stably express wild-type
(exoCHK1(WT)) and mutated CHK1 phosphorylation sites
(exoCHK1(S296A), exoCHK1(S317A), and exoCHK1(S345A)), and
then examined the combined effects of the mutations on each
DNA damage-induced phosphorylation (Fig. 3A). Cells expressing
both exoCHK1 and endoCHK1 were treated with Cis for 24 h
and the proteins were analyzed by Western blotting. Ser296
cis-autophosphorylation was abolished in exoCHK1 (S296A),
exoCHK1(S317A), and exoCHK1(S345A). This result demonstrates
that Ser296 cis-autophosphorylation is dependent on both
Ser317 and Ser345. Furthermore, the phosphorylation of Ser317
and Ser345 in exoCHK1(S296A) were induced to levels similar to
those in exoCHK1(WT). Moreover we conﬁrmed the effects of
CHK1 activity (that is Ser296 autophosphorylation) on Ser317 or
Ser345 phosphorylation by the inhibition of cis-autophosphoryla-
tion with a CHK1 inhibitor, SB218078 (Fig. 3B). Cis or Etp-induced
Ser296 cis-autophosphorylation was inhibited in a CHK1 inhibitor
dose-dependent manner. However, Ser317 and Ser345 phosphory-
lation were not affected by CHK1 inhibitor treatment. These results
indicate that Ser296 cis-autophosphorylation does not signiﬁ-
cantly affect phosphorylation of Ser317 and Ser345.4. Discussion
In this study, we demonstrated that DNA damage-induced
Ser296 autophosphorylation of CHK1 is mainly regulated by an
intramolecular mechanism (Fig. 2). We demonstrated this by using
mutations of two amino acid residues (K38A and D130A) that have
different roles in kinase activity [3,24,25]. Our ﬁnding means that
CHK1 possesses not only trans-phosphorylation (intermolecular
phosphorylation) activity which affects downstream factors but
also cis-autophosphorylation (intramolecular autophosphoryla-
tion) activity directed towards itself. The sequence surrounding
human CHK1 Ser296 is H-I-Q-H-S⁄-N-L-D, although the known CHK1
consensus sequence is (R/K)-(R/K)-(X)-(X)-(S⁄/T⁄)-(F/Q/S)-(S/E)-(D/S/
E/P) [32]. It appears that the surrounding sequence of Ser296 is
not the general CHK1 consensus sequence. Taken together, there
may be a difference between the preferential sequences related
to trans-phosphorylation compared with cis-autophosphorylation.
These facts may also suggest that the kinetics of trans-phosphory-
lation for the downstream factors is different from that of
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Fig. 3. The relationships between DNA damage-induced phosphorylation at Ser296,
Ser317, and Ser345. (A) U2OS cells stably expressing the indicated exoCHK1s were
treated with 5 lM Cis for 9 h. Western blotting was performed with the indicated
antibodies. An anti-b-actin blot was used as a loading control. The induction rates of
Ser296, Ser317, or Ser345 phosphorylation by Cis treatment in the indicated cells
are shown. After normalization of each phosphorylation signal from exoCHK1 by
the total exoCHK1 protein, we deﬁned the value of each normalized phosphory-
lation signal exoCHK1(WT) without Cis treatment as 1. Based on the deﬁnition,
relative levels of phosphorylation (pSer296, pSer317 or pSer345 phosphorylation
levels) and levels of phosphorylation increased by Cis treatment (Increase) were
shown. (B) In the presence of the indicated doses of CHK1 inhibitor SB218078, U2OS
cells were treated with 5 lM Cis or 2 lM Etp for 9 h. The cells were then harvested
and analyzed by Western blotting with the indicated antibodies.
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hypothesis, further analysis of the kinetics and the change of
three-dimensional structure for cis-autophosphorylation are
required. In the past, it has been reported that core cell cycle
checkpoint molecules such as ATM, ATR, CHK1 and CHK2 have
autophosphorylation site(s), and dimerization (or oligomerization)
of each of these kinases (except CHK1) directly contributes to the
regulation of kinase activity [22,33–36]. Our new ﬁndings about
CHK1 cis-autophosphorylation may provide additional support to
the notion that CHK1 does not dimerize (oligomerized) [37].
Nevertheless, there remains the possibility that an intermolecular
mechanism might be involved in Ser296 autophosphorylation,
because in the reaction combination of wild-type and kinase
dead forms of recombinant CHK1, a modest increase of Ser296
phosphorylation of kinase dead forms of CHK1 was observed
(Fig. 2D). It would be very interesting to observe whether a switch
between of cis/trans autophosphorylation can occur under any
physiological condition.
We showed that Ser296 cis-autophosphorylation is dependent
on ATR and both Ser317 and Ser345 phosphorylation (Figs. 1 and 3).
Considering that phosphorylation of Ser317 and Ser345 is
predominantly catalyzed by ATR [1], ATR-mediated Ser317
and Ser345 phosphorylation would be required for Ser296cis-autophosphorylation. While the ATR dependency of Ser296
autophosphorylation was certainly observed, the reduction in the
level of autophosphorylation in ATR knockdown or hypomorphic
cells was evident. These facts could be explained by a low level
of ATR activity remaining in both the ATR knockdown and hypo-
morphic cells. On the other hand, Ser317 and Ser345, which are
SQ motifs, are consensus sequences targeted by DNA damage-
responsive PIKKs such as ATM and DNA-PKcs as well as ATR
[38,39]. Also, considering that contributions of these PIKKs vary
according to different types of DNA damage and that the functions
of DNA damage-responsive PIKKs can overlap in some cases
[1,38,39], the involvement of ATM or DNA-PKcs in Ser317 and
Ser345 phosphorylation would not be excluded. Interestingly,
spontaneous Ser296 phosphorylation was also observed in cells
without the treatment of DNA damaging agents. As shown in
Fig. 3A, the spontaneous Ser296 autophosphorylations in
exoCHK1(S317A) and exoCHK1(S345A) was present at very low
levels. Furthermore Ser296, Ser317 and Ser345 of both
exoCHK1(WT) and endoCHK1 are phosphorylated at low levels
under conditions without DNA damaging agents. Considering that
spontaneous DNA damage occurs in cultured cells [40], we suggest
that spontaneous DNA damage could contribute to this low-level
phosphorylation. These ﬁndings mean that spontaneous Ser296
autophosphorylation is also dependent upon both Ser317 and
Ser345 phosphorylations as well as that induced by DNA damage-
inducing agents. We may consider two possibilities necessary for
Ser317 and Ser345 phosphorylation. One is the effect on the
structure of CHK1, because it has been reported that the phosphor-
ylation of Ser317 and Ser345 induced by DNA damage is required
to release the interaction between the auto-inhibitory region and
the kinase domain, resulting in the activation of the kinase activity
[1]. The other is the effect on the localization of CHK1, because it
has been thought that these phosphorylations are required for
the appropriate intracellular localization of CHK1 in the DNA
damage response [1].
Since CHK1 inhibition enhances cellular sensitivity to anti-cancer
drugs such as inducers of DNA damage, it has been thought that
CHK1 inhibitors may be a potent tool for cancer therapy. However,
the off-target effects of such drugs tend to pose problems, as most
CHK1 inhibitors target the ATP binding pocket [1]. Since Ser296
autophosphorylation contributes to G2/M checkpoint regulation,
our ﬁndings suggest that the development of CHK1 inhibitors
with a novel mode of action that speciﬁcally inhibits Ser296
cis-autophosphorylation might be a useful strategy. The exploration
of the CHK1 cis-autophosphorylation mechanism, as described in
this study, may lead to improved understanding of CHK1-regulated
signal transduction and aid the development of novel CHK1
inhibitors.
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